Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14538465 | 0.85 | TTK (0.46) | TTK | |
| SCHEMBL13155404 | 0.82 | TTK (0.31) | TTK | |
| SCHEMBL13693181 | 0.81 | TTK (0.31) | TTK | |
| SCHEMBL13954633 | 0.78 | — | — | |
| SCHEMBL31244494 | 0.78 | — | — | |
| SCHEMBL9936039 | 0.78 | — | — | |
| SCHEMBL9938786 | 0.75 | TTK (0.52) | TTK | |
| SCHEMBL19747465 | 0.75 | ADORA1 (0.37) | — | |
| SCHEMBL19748170 | 0.74 | IKBKB (0.36) | TTK | |
| SCHEMBL14507499 | 0.74 | TTK (0.55) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024254536-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9468642-B2 | Imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-18 | — | — | US | disclosed |
| US-9284317-B2 | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9284317-B2 | Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9212184-B2 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-9212184-B2 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-9212184-B2 | 6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-15 | — | — | US | disclosed |
| US-9199999-B2 | Substituted imidazopyrazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | disclosed |
| US-7511040-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511040-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2009017701-A2 | ANTI-MITOTIC AGENT AND AURORA KINASE INHIBITOR COMBINATION AS ANTI-CANCER TREATMENT | SCHERING CORPORATION (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008156614-A2 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION | 2007-05-24 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | TTK 69/4885 |
| US-20070117804-A1 | Imidazopyrazines as protein kinase inhibitors | CHEK1, CHEK2, CDKN1A | TTK 45/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | TTK 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.